Meta Assists Junshi Biosciences -Toripalimab New Indication to Obtain Market Approval

Richard Tadd Blog

On April 8, 2021, Toripalimab injection(recombinant humanized anti-PD-1 monoclonal antibody injection, JS001) is used to treat locally advanced or metastatic bladder urothelium after failure of standard treatment Cancer (UC) indications were officially approved by NMPA. Meta Clinical Technology Co. Ltd., undertook the data management service of this study, and cooperated with Junshi and contributed to the application and approval of …